{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:37:55Z","timestamp":1791895075022,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100020483","name":"Insmed","doi-asserted-by":"publisher","award":["Insmed"],"award-info":[{"award-number":["Insmed"]}],"id":[{"id":"10.13039\/100020483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fatigue symptoms contribute to the burden of\n                      <jats:italic>Mycobacterium avium<\/jats:italic>\n                      complex (MAC) lung disease. This study evaluated the psychometric properties of the Patient Reported Outcomes Measurement Information System Short Form v1.0 \u2013 Fatigue 7a (PROMIS-F SF-7a) in adults with a new or recurrent diagnosis of MAC lung disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the ARISE (NCT04677543) and ENCORE (NCT04677569) phase 3 trials were analyzed. Modern psychometric methods were employed to confirm the structural validity of the PROMIS-F SF-7a within this context of use. Classical methods were used to confirm the reliability and validity of the PROMIS-F SF-7a within this context of use. Internal consistency (McDonald\u2019s omega, Cronbach\u2019s alpha), test-retest reliability (two-way mixed effects intraclass correlation coefficient [ICC(2,1)]), and known-groups validity across Patient Global Impression of Severity (PGI-S) Fatigue groups were estimated. Convergent validity (Pearson correlations) was assessed by correlating PROMIS-F SF-7a scores with scores on the Exacerbations of Chronic Pulmonary Disease Tool (EXACT), EXACT Respiratory Symptoms (E-RS), St. George Respiratory Questionnaire (SGRQ), and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. Meaningful within-patient change (MWPC) thresholds were determined using anchor-based methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The baseline sample included 231 patients (99 ARISE, 132 ENCORE). The cross-sectional validation sample comprised 230 patients (excluding 1 ARISE patient with missing item-level PROMIS-F SF-7a data). The longitudinal validation analysis sample comprised all 99 ARISE patients. Modern psychometric methods supported the relevance of all items and a unidimensional unit-weighted sum score for the PROMIS-F SF-7a. The PROMIS-F SF-7a demonstrated strong internal consistency (Cronbach\u2019s alpha: 0.86), test-retest reliability (ICC[2, 1]: 0.76), and convergent validity (FACIT-Fatigue: \u22120.80, EXACT: 0.56, E-RS: 0.52, SGRQ: 0.66). Known-groups validity was demonstrated across PGI-S Fatigue groups. The MWPC analyses supported a \u22124.00-point median change from baseline (95% CI: \u22123.00 to \u22126.00 points) as the estimated threshold of clinically meaningful within-patient improvement for the PROMIS-F SF-7a.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The PROMIS-F SF-7a is a robust, sensitive, and responsive measure of fatigue in adult patients with a new or recurrent diagnosis of MAC lung disease. It is content and psychometrically valid and appears to have interpretability to assess a threshold of MWPC for fatigue symptoms in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov. NCT04677543, registered 16 December 2020,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04677543\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT04677543<\/jats:ext-link>\n                      . NCT04677569, registered 16 December 2020,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT04677569\" ext-link-type=\"uri\">https:\/\/www.clinicaltrials.gov\/study\/NCT04677569<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-025-00944-8","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:47:27Z","timestamp":1760615247000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Psychometric validation of the PROMIS Fatigue-Short Form 7a in adults with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung disease: the ARISE and ENCORE studies"],"prefix":"10.1186","volume":"9","author":[{"given":"Kevin C.","family":"Mange","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Nevoret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayton W.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shauna","family":"McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Podger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryant","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"944_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijid.2022.10.013","volume":"125","author":"VN Dahl","year":"2022","unstructured":"Dahl VN, M\u00f8lhave M, Fl\u00f8e A et al (2022) Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review. Int J Infect Dis 125:120\u2013131. https:\/\/doi.org\/10.1016\/j.ijid.2022.10.013","journal-title":"Int J Infect Dis"},{"issue":"3","key":"944_CR2","first-page":"210","volume":"6","author":"MM Johnson","year":"2014","unstructured":"Johnson MM, Odell JA (2014) Nontuberculous mycobacterial pulmonary infections. J Thorac Dis 6(3):210\u2013220","journal-title":"J Thorac Dis"},{"issue":"8","key":"944_CR3","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1164\/rccm.201111-2016OC","volume":"185","author":"J Adjemian","year":"2012","unstructured":"Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR (2012) Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 185(8):881\u2013886. https:\/\/doi.org\/10.1164\/rccm.201111-2016OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"944_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pulmoe.2017.12.005","volume":"24","author":"JD Chalmers","year":"2018","unstructured":"Chalmers JD, Aksamit T, Carvalho ACC, Rendon A, Franco I (2018) Non-tuberculous mycobacterial pulmonary infections. Pulmonology 24(2):120\u2013131. https:\/\/doi.org\/10.1016\/j.pulmoe.2017.12.005","journal-title":"Pulmonology"},{"issue":"11","key":"944_CR5","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1080\/17476348.2021.1987891","volume":"15","author":"J van Ingen","year":"2021","unstructured":"van Ingen J, Obradovic M, Hassan M et al (2021) Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex - disease burden, unmet needs, and advances in treatment developments. Expert Rev Respir Med 15(11):1387\u20131401. https:\/\/doi.org\/10.1080\/17476348.2021.1987891","journal-title":"Expert Rev Respir Med"},{"issue":"6","key":"944_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.5588\/ijtld.15.0460","volume":"20","author":"M Hama","year":"2016","unstructured":"Hama M, Ushiki A, Kosaka M et al (2016) Health-related quality of life in patients with pulmonary non-tuberculous mycobacteria infection. Int J Tuberc Lung Dis 20(6):747\u2013752. https:\/\/doi.org\/10.5588\/ijtld.15.0460","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"944_CR7","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.rmed.2011.08.004","volume":"105","author":"M Mehta","year":"2011","unstructured":"Mehta M, Marras TK (2011) Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med 105(11):1718\u20131725. https:\/\/doi.org\/10.1016\/j.rmed.2011.08.004","journal-title":"Respir Med"},{"key":"944_CR8","unstructured":"Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA) (2016) The voice of the patient: a series of reports from the U.S. Food and Drug Administration\u2019s (FDA\u2019s) Patient-Focused Drug Development Initiative: non-tuberculous mycobacterial (NTM) lung infection. Public Meeting: October 15, 2015. https:\/\/www.fda.gov\/media\/96932\/download. Accessed 17 May 2024"},{"issue":"9","key":"944_CR9","doi-asserted-by":"publisher","first-page":"S379","DOI":"10.1513\/AnnalsATS.201605-387WS","volume":"13","author":"E Henkle","year":"2016","unstructured":"Henkle E, Aksamit T, Barker A et al (2016) Patient-centered research priorities for pulmonary nontuberculous mycobacteria (NTM) infection. An NTM research consortium workshop report. Ann Am Thorac Soc 13(9):S379\u2013S84. https:\/\/doi.org\/10.1513\/AnnalsATS.201605-387WS","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"944_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.15326\/jcopdf.2020.0184","volume":"8","author":"V Pravosud","year":"2021","unstructured":"Pravosud V, Mannino DM, Prieto D et al (2021) Symptom burden and medication use among patients with nontuberculous mycobacterial lung disease. Chronic Obstr Pulm Dis 8(2):243\u2013254. https:\/\/doi.org\/10.15326\/jcopdf.2020.0184","journal-title":"Chronic Obstr Pulm Dis"},{"key":"944_CR11","unstructured":"US Food and Drug Administration (2009) Guidance for Industry: Patient-reported outcome measures: use in medical product development to support labeling claims. Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD. https:\/\/www.fda.gov\/media\/77832\/download. Accessed 26 June 2025"},{"issue":"2","key":"944_CR12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.chest.2020.08.2055","volume":"159","author":"PA Flume","year":"2021","unstructured":"Flume PA, Griffith DE, Chalmers JD et al (2021) Development of drugs for nontuberculous mycobacterial disease: clinicians\u2019 interpretation of a US Food and Drug Administration workshop. Chest 159(2):537\u2013543. https:\/\/doi.org\/10.1016\/j.chest.2020.08.2055","journal-title":"Chest"},{"issue":"4","key":"944_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/nnr.0000000000000162","volume":"65","author":"S Ameringer","year":"2016","unstructured":"Ameringer S, Elswick RKJ, Menzies V et al (2016) Psychometric evaluation of the Patient-Reported Outcomes Measurement Information System Fatigue-Short Form across diverse populations. Nurs Res 65(4):279\u2013289. https:\/\/doi.org\/10.1097\/nnr.0000000000000162","journal-title":"Nurs Res"},{"key":"944_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jclinepi.2015.08.037","volume":"73","author":"D Cella","year":"2016","unstructured":"Cella D, Lai J-S, Jensen SE et al (2016) PROMIS Fatigue item bank had clinical validity across diverse chronic conditions. J Clin Epidemiol 73:128\u2013134. https:\/\/doi.org\/10.1016\/j.jclinepi.2015.08.037","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"944_CR15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s11136-011-0011-8","volume":"21","author":"KF Cook","year":"2012","unstructured":"Cook KF, Bamer AM, Roddey TS et al (2012) A PROMIS fatigue short form for use by individuals who have multiple sclerosis. Qual Life Res 21(6):1021\u20131030. https:\/\/doi.org\/10.1007\/s11136-011-0011-8","journal-title":"Qual Life Res"},{"issue":"1","key":"944_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s41687-019-0155-9","volume":"3","author":"SE Yount","year":"2019","unstructured":"Yount SE, Atwood C, Donohue J et al (2019) Responsiveness of PROMIS\u00ae to change in chronic obstructive pulmonary disease. J Patient Rep Outcomes 3(1):65. https:\/\/doi.org\/10.1186\/s41687-019-0155-9","journal-title":"J Patient Rep Outcomes"},{"key":"944_CR17","unstructured":"US Food and Drug Administration (2022) Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD. https:\/\/www.fda.gov\/media\/159500\/download. Accessed 5 December 2023"},{"key":"944_CR18","unstructured":"US Food and Drug Administration (2022) Patient-Focused Drug Development: Methods to Identify What is Important to Patients. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD. https:\/\/www.fda.gov\/media\/131230\/download. Accessed 27 June 2025"},{"issue":"2","key":"944_CR19","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s12325-024-03064-9","volume":"42","author":"KP McCarrier","year":"2025","unstructured":"McCarrier KP, Hassan M, Yuen DW et al (2025) Content validation of the QOL-B-RD and PROMIS-F SF-7a to measure respiratory and fatigue symptoms of MAC lung disease. Adv Ther 42(2):935\u2013976. https:\/\/doi.org\/10.1007\/s12325-024-03064-9","journal-title":"Adv Ther"},{"key":"944_CR20","unstructured":"NCT04677543 Validation of Patient Reported Outcome Measures in Participants with Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex (ARISE). https:\/\/clinicaltrials.gov\/study\/NCT04677543. Accessed 20 May 2024"},{"key":"944_CR21","unstructured":"NCT04677569 Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex (ENCORE). https:\/\/www.clinicaltrials.gov\/study\/NCT04677569. Accessed 20 May 2024"},{"key":"944_CR22","unstructured":"HealthMeasures (2024) User Manual and Scoring Instructions: PROMIS Fatigue. https:\/\/www.healthmeasures.net\/administrator\/components\/com_instruments\/uploads\/PROMIS%20Fatigue%20User%20Manual%20and%20Scoring%20Instructions_29May2024.pdf. Accessed 4 June 2024"},{"issue":"10 Suppl","key":"944_CR23","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.apmr.2010.08.033","volume":"92","author":"JS Lai","year":"2011","unstructured":"Lai JS, Cella D, Choi S et al (2011) How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. Arch Phys Med Rehabil 92(10 Suppl):S20\u2013S27. https:\/\/doi.org\/10.1016\/j.apmr.2010.08.033","journal-title":"Arch Phys Med Rehabil"},{"key":"944_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1067\/mob.2003.379","volume":"189","author":"I Yalcin","year":"2003","unstructured":"Yalcin I, Bump RC (2003) Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 189:98\u2013101. https:\/\/doi.org\/10.1067\/mob.2003.379","journal-title":"Am J Obstet Gynecol"},{"key":"944_CR25","first-page":"218","volume-title":"ECDEU assessment manual for psychopharmacology","year":"1976","unstructured":"028 CGI Clinical Global Impressions (1976) In: Guy W (ed) ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare, Rockville, MD, pp 218\u2013222"},{"key":"944_CR26","unstructured":"US Food and Drug Administration (2023) Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making. Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, MD. https:\/\/www.fda.gov\/media\/166830\/download. Accessed 25 June 2024"},{"issue":"6","key":"944_CR27","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1378\/chest.10-1240","volume":"139","author":"PW Jones","year":"2011","unstructured":"Jones PW, Chen W-H, Wilcox TK, Sethi S, Leidy NK (2011) Characterizing and quantifying the symptomatic features of COPD exacerbations. Chest 139(6):1388\u20131394. https:\/\/doi.org\/10.1378\/chest.10-1240","journal-title":"Chest"},{"issue":"8","key":"944_CR28","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/j.1524-4733.2010.00772.x","volume":"13","author":"NK Leidy","year":"2010","unstructured":"Leidy NK, Wilcox TK, Jones PW et al (2010) Development of the EXAcerbations of Chronic obstructive pulmonary disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health 13(8):965\u2013975. https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00772.x","journal-title":"Value Health"},{"issue":"3","key":"944_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1164\/rccm.201005-0762OC","volume":"183","author":"NK Leidy","year":"2011","unstructured":"Leidy NK, Wilcox TK, Jones PW et al (2011) Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 183(3):323\u2013329. https:\/\/doi.org\/10.1164\/rccm.201005-0762OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"944_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12931-014-0124-z","volume":"15","author":"NK Leidy","year":"2014","unstructured":"Leidy NK, Murray LT, Monz BU et al (2014) Measuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms tool (E-RS) in three clinical trials. Respir Res 15(1):124. https:\/\/doi.org\/10.1186\/s12931-014-0124-z","journal-title":"Respir Res"},{"issue":"5","key":"944_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1136\/thoraxjnl-2013-204428","volume":"69","author":"NK Leidy","year":"2014","unstructured":"Leidy NK, Sexton CC, Jones PW et al (2014) Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary. Thorax 69(5):424\u2013430. https:\/\/doi.org\/10.1136\/thoraxjnl-2013-204428","journal-title":"Thorax"},{"issue":"6","key":"944_CR32","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","volume":"145","author":"PW Jones","year":"1992","unstructured":"Jones PW, Quirk FH, Baveystock CM, Littlejohns P (1992) A self-complete measure of health status for chronic airflow limitation: the St. George\u2019s Respiratory Questionnaire. Am J Respir Crit Care Med 145(6):1321\u20131327. https:\/\/doi.org\/10.1164\/ajrccm\/145.6.1321","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"944_CR33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.pmrj.2010.04.017","volume":"2","author":"E Smith","year":"2010","unstructured":"Smith E, Lai J-S, Cella D (2010) Building a measure of fatigue: the Functional Assessment of Chronic Illness Therapy Fatigue scale. PM R 2(5):359\u2013363. https:\/\/doi.org\/10.1016\/j.pmrj.2010.04.017","journal-title":"PM R"},{"key":"944_CR34","unstructured":"Revelle W. Psych: procedures for psychological, psychometric, and personality research. R package version 2.3.6. Northwestern University, Evanston, Illinois. https:\/\/personality-project.org\/r\/psych\/psych-manual.pdf"},{"issue":"4","key":"944_CR35","first-page":"100","volume":"34","author":"F Samejima","year":"1969","unstructured":"Samejima F (1969) Estimation of latent ability using a response pattern of graded scores. Psychometrika Monogr Supplement 34(4):100","journal-title":"Psychometrika Monogr Supplement"},{"key":"944_CR36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1037\/1082-989X.1.2.130","volume":"1","author":"RC MacCallum","year":"1996","unstructured":"MacCallum RC, Browne MW, Sugawara HM (1996) Power analysis and determination of sample size for covariance structure modeling. Psychol Methods 1:130\u2013149","journal-title":"Psychol Methods"},{"issue":"1","key":"944_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10705519909540118","volume":"6","author":"L Hu","year":"1999","unstructured":"Hu L, Bentler PM (1999) Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model 6(1):1\u201355. https:\/\/doi.org\/10.1080\/10705519909540118","journal-title":"Struct Equ Model"},{"issue":"2","key":"944_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/BF02295289","volume":"55","author":"WF Stout","year":"1990","unstructured":"Stout WF (1990) A new item response theory modeling approach with applications to unidimensionality assessment and ability estimation. Psychometrika 55(2):293\u2013325. https:\/\/doi.org\/10.1007\/BF02295289","journal-title":"Psychometrika"},{"issue":"4","key":"944_CR39","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/BF02289858","volume":"69","author":"JMF Ten Berge","year":"2004","unstructured":"Ten Berge JMF, So\u010dan G (2004) The greatest lower bound to the reliability of a test and the hypothesis of unidimensionality. Psychometrika 69(4):613\u2013625. https:\/\/doi.org\/10.1007\/BF02289858","journal-title":"Psychometrika"},{"key":"944_CR40","volume-title":"Test theory: A unified treatment","author":"RP McDonald","year":"1999","unstructured":"McDonald RP (1999) Test theory: a unified treatment. Lawrence Erlbaum Associates, Mahwah, NJ"},{"issue":"2","key":"944_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1037\/met0000045","volume":"21","author":"A Rodriguez","year":"2016","unstructured":"Rodriguez A, Reise SP, Haviland MG (2016) Evaluating bifactor models: calculating and interpreting statistical indices. Psychol Methods 21(2):137\u2013150. https:\/\/doi.org\/10.1037\/met0000045","journal-title":"Psychol Methods"},{"issue":"3","key":"944_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2307\/1165285","volume":"22","author":"W-H Chen","year":"1997","unstructured":"Chen W-H, Thissen D (1997) Local dependence indexes for item pairs using item response theory. J Educ Behav Stat 22(3):265\u2013289. https:\/\/doi.org\/10.2307\/1165285","journal-title":"J Educ Behav Stat"},{"issue":"3","key":"944_CR43","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1177\/0013164412464875","volume":"73","author":"CM Woods","year":"2013","unstructured":"Woods CM, Cai L, Wang M (2013) The Langer-improved Wald test for DIF testing with multiple groups: evaluation and comparison to two-group IRT. Educ Psychol Meas 73(3):532\u2013547. https:\/\/doi.org\/10.1177\/0013164412464875","journal-title":"Educ Psychol Meas"},{"issue":"6","key":"944_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v048.i06","volume":"48","author":"RP Chalmers","year":"2012","unstructured":"Chalmers RP (2012) mirt: a multidimensional item response theory package for the R environment. J Stat Softw 48(6):1\u201329. https:\/\/doi.org\/10.18637\/jss.v048.i06","journal-title":"J Stat Softw"},{"key":"944_CR45","unstructured":"Fox J (2022) polychor: Polychoric and Polyserial Correlations. R package. 2022; Version 0.8.1. https:\/\/cran.r-project.org\/web\/packages\/polycor\/polycor.pdf"},{"key":"944_CR46","doi-asserted-by":"crossref","unstructured":"Mokkink LB, Prinsen CAC, Patrick DL et al (2018) COSMIN methodology for systematic reviews of patient-reported outcome measures (PROMs): user manual version 1.0. https:\/\/cosmin.nl\/wp-content\/uploads\/COSMIN-syst-review-for-PROMs-manual_version-1_feb-2018.pdf","DOI":"10.1007\/978-3-319-69909-7_2972-2"},{"issue":"5","key":"944_CR47","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","volume":"27","author":"CAC Prinsen","year":"2018","unstructured":"Prinsen CAC, Mokkink LB, Bouter LM et al (2018) COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res 27(5):1147\u20131157. https:\/\/doi.org\/10.1007\/s11136-018-1798-3","journal-title":"Qual Life Res"},{"issue":"1","key":"944_CR48","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","volume":"60","author":"CB Terwee","year":"2007","unstructured":"Terwee CB, Bot SDM, de Boer MR et al (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60(1):34\u201342. https:\/\/doi.org\/10.1016\/j.jclinepi.2006.03.012","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"944_CR49","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","volume":"1","author":"KO McGraw","year":"1996","unstructured":"McGraw KO, Wong SP (1996) Forming inferences about some intraclass correlation coefficients. Psychol Methods 1(1):30\u201346","journal-title":"Psychol Methods"},{"issue":"1","key":"944_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/2168479015622667","volume":"50","author":"CD Coon","year":"2016","unstructured":"Coon CD, Cappelleri JC (2016) Interpreting change in scores on patient-reported outcome instruments. Ther Innov Regul Sci 50(1):22\u201329. https:\/\/doi.org\/10.1177\/2168479015622667","journal-title":"Ther Innov Regul Sci"},{"key":"944_CR51","doi-asserted-by":"publisher","unstructured":"Gruet M (2018) Fatigue in chronic respiratory diseases: theoretical framework and implications for real-life performance and rehabilitation. Front Physiol 9. https:\/\/doi.org\/10.3389\/fphys.2018.01285","DOI":"10.3389\/fphys.2018.01285"},{"issue":"11","key":"944_CR52","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","volume":"63","author":"D Cella","year":"2010","unstructured":"Cella D, Riley W, Stone A et al (2010) The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008. J Clin Epidemiol 63(11):1179\u20131194. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.04.011","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"944_CR53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41687-019-0105-6","volume":"3","author":"CO Bingham III","year":"2019","unstructured":"Bingham III CO, Gutierrez AK, Butanis A et al (2019) PROMIS fatigue short forms are reliable and valid in adults with rheumatoid arthritis. J Patient Rep Outcomes 3(1):14. https:\/\/doi.org\/10.1186\/s41687-019-0105-6","journal-title":"J Patient Rep Outcomes"},{"issue":"11","key":"944_CR54","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1007\/s11136-015-1010-y","volume":"24","author":"KE Flynn","year":"2015","unstructured":"Flynn KE, Dew MA, Lin L et al (2015) Reliability and construct validity of PROMIS\u00ae measures for patients with heart failure who undergo heart transplant. Qual Life Res 24(11):2591\u20132599. https:\/\/doi.org\/10.1007\/s11136-015-1010-y","journal-title":"Qual Life Res"},{"issue":"1","key":"944_CR55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12981-017-0146-y","volume":"14","author":"LE Gibbons","year":"2017","unstructured":"Gibbons LE, Fredericksen R, Batey DS et al (2017) Validity assessment of the PROMIS fatigue domain among people living with HIV. AIDS Res Ther 14(1):21. https:\/\/doi.org\/10.1186\/s12981-017-0146-y","journal-title":"AIDS Res Therapy"},{"issue":"1","key":"944_CR56","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s41687-023-00645-0","volume":"7","author":"BG Feagan","year":"2023","unstructured":"Feagan BG, Sandborn WJ, Sands BE et al (2023) Qualitative and psychometric evaluation of the PROMIS\u00ae-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease. J Patient Rep Outcomes 7(1):115. https:\/\/doi.org\/10.1186\/s41687-023-00645-0","journal-title":"J Patient-Reported Outcomes"},{"key":"944_CR57","doi-asserted-by":"publisher","first-page":"152111","DOI":"10.1016\/j.semarthrit.2022.152111","volume":"58","author":"D DiRenzo","year":"2023","unstructured":"DiRenzo D, Saygin D, de Groot I et al (2023) Reliability and validity of PROMIS physical function, pain interference, and fatigue as patient reported outcome measures in adult idiopathic inflammatory myopathies: international study from the OMERACT myositis working group. Semin Arthritis Rheum 58:152111. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152111","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"944_CR58","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1037\/hea0000696","volume":"38","author":"AK Hildenbrand","year":"2019","unstructured":"Hildenbrand AK, Quinn CT, Mara CA et al (2019) A preliminary investigation of the psychometric properties of PROMIS\u00ae scales in emerging adults with sickle cell disease. Health Psychol 38(5):386\u2013390. https:\/\/doi.org\/10.1037\/hea0000696","journal-title":"Health Psychol"},{"issue":"5","key":"944_CR59","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jclinepi.2010.11.018","volume":"64","author":"KJ Yost","year":"2011","unstructured":"Yost KJ, Eton DT, Garcia SF, Cella D (2011) Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol 64(5):507\u2013516. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.11.018","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"944_CR60","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA et al (2007) An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175(4):367\u2013416. https:\/\/doi.org\/10.1164\/rccm.200604-571ST","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"944_CR61","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jclinepi.2008.06.003","volume":"62","author":"NW Scott","year":"2009","unstructured":"Scott NW, Fayers PM, Aaronson NK et al (2009) A simulation study provided sample size guidance for differential item functioning (DIF) studies using short scales. J Clin Epidemiol 62(3):288\u2013295. https:\/\/doi.org\/10.1016\/j.jclinepi.2008.06.003","journal-title":"J Clin Epidemiol"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00944-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-025-00944-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00944-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:15:28Z","timestamp":1781612128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-025-00944-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["944"],"URL":"https:\/\/doi.org\/10.1186\/s41687-025-00944-8","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies were conducted in accordance with the Declaration of Helsinki. Local institutional review boards or independent ethics committees approved the study protocols. All patients provided written or electronic informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Part of this article has been presented at the ISPOR 2024 Conference, Atlanta, GA, May 5-8, 2024.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentation"}},{"value":"KCM, MH, MN, and DWY are employees and shareholders of Insmed Incorporated. DS, BB, SM, and LP were employees of OPEN Health Group at the time of study, which was funded by Insmed Incorporated. CLD reports grant support, advisory board fees, and consulting fees from Insmed Incorporated. CLD also reports grant support from AN2 Therapeutics, Bugworks, Paratek Pharmaceuticals, Juvabis; advisory board work with AN2 Therapeutics, AstraZeneca, Cepheid, Galapagos, Hyfe, MannKind, Matinas Biopharma, NobHill, Spero Therapeutics, Zambon; consulting with Genentech, Pfizer; data monitoring committee work with Otsuka Pharmaceutical, Bill and Melinda Gates Foundation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}